

AD _____

Award Number: W81XWH-10-1-0426

TITLE: Targeting Breast Cancer Recurrence via Hedgehog-Mediated Sensitization of Breast Cancer Stem Cells

PRINCIPAL INVESTIGATOR: Dr. James DiRenzo

CONTRACTING ORGANIZATION: Dartmouth College
Hanover, NH 03755

REPORT DATE: July 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-07-2011		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 JUN 2010 - 14 JUN 2011	
4. TITLE AND SUBTITLE Targeting Breast Cancer Recurrence via Hedgehog-Mediated Sensitization of Breast Cancer Stem Cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-10-1-0426	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. James DiRenzo E-Mail: james.direnzo@dartmouth.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dartmouth College Hanover, NH 03755				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Abstract on next page.					
15. SUBJECT TERMS p63, stem cell, hedgehog, breast cancer, quiescence					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 24	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

14. ABSTRACT

Research supported by this award aims to determine if targeting the hedgehog signaling pathway in breast cancer can reduce breast cancer recurrence. In the United States and other countries with access to advanced cancer care, local and distant breast cancer recurrence accounts for ~95% of breast cancer mortality. Additionally, the life-time risk of breast cancer recurrence is greater than the life-time risk of developing breast cancer in the general population. Together these two statements indicate that current treatments do not efficiently reduce the risk of disease recurrence. Disease recurrence is believed to be the result of a subset of tumor cells with two distinct features; broad-spectrum resistance to therapeutics and tumorigenicity. Our previous studies identified a regulatory relationship between $\Delta Np63\alpha$ a protein that is required for long-term preservation of epithelial stem cells and the hedgehog-signaling pathway that governed stem cell quiescence. Stem cell quiescence is necessary to preserve long-term replicative capacity while simultaneously avoiding the detrimental effects of excessive proliferation. It is also a potent blockade to cellular differentiation. Based upon this we put forth the hypothesis that the hedgehog signaling pathway could be targeted to subvert quiescence in stem cell populations. Doing so would force these cells back into the cell cycle, possibly sensitizing them to adjuvant cancer therapeutics. To test this hypothesis we developed three specific tasks that are described in detail in the Statement of Work. Since this award was a collaborative IDEA award we sought to take advantage of the hedgehog-signaling expertise of Dr. David J. Robbins and the mammary stem cell and breast cancer expertise of Dr. James DiRenzo. What follows is a detailed description of progress towards the completion of the research supported by this award.

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1-9
Key Research Accomplishments.....	9-10
Reportable Outcomes.....	10
Conclusion.....	10-11
References.....	12
Appendices.....	13-20

Prologue: In support of Award number W81XWH-10-1-0430, we are pleased to present the following annual report detailing progress made towards the completion of work described in the Statement of Work associated with this award.

Introduction

The purpose of the research supported by this award is to determine if targeting the hedgehog signaling pathway in breast cancer can reduce breast cancer recurrence. Two specific facts about breast cancer recurrence highlight the need for better treatment modalities that target and prevent disease recurrence.

1. In the United States and other countries with access to advanced cancer care, local and distant breast cancer recurrence accounts for ~95% of breast cancer mortality (Jemal et al., 2010).
2. The life-time risk of breast cancer recurrence among survivors is greater than the life-time risk of developing breast cancer in the general population (Jemal et al., 2010).

Together these two statements suggest that while substantial progress has been made in treating primary breast cancer, those treatments do not efficiently reduce the risk of disease recurrence. Therefore there is a need for novel treatment strategies. Disease recurrence is believed to be the result of a subset of tumor cells with two distinct features; broad-spectrum resistance to therapeutics and tumorigenicity (Hurt and Farrar, 2008; Pardal et al., 2003; Polyak and Weinberg, 2009; Woodward et al., 2005). Our previous studies (Li et al., 2008) identified a regulatory relationship between $\Delta Np63\alpha$ a protein that is required for long-term preservation of epithelial stem cells (Li et al., 2008; Mills et al., 1999; Yang et al., 1999) and the hedgehog-signaling pathway that governed stem cell quiescence. Stem cell quiescence is necessary to preserve long-term replicative capacity while simultaneously avoiding the detrimental effects of excessive proliferation. It is also a potent blockade to cellular differentiation (Coller et al., 2006). Based upon this we put forth the hypothesis that the hedgehog signaling pathway could be targeted to subvert quiescence in stem cell populations. Doing so would force these cells back into the cell cycle, possibly sensitizing them to adjuvant cancer therapeutics. To test this hypothesis we developed three specific tasks that are described in detail in the Statement of Work. Since this award was a collaborative IDEA award we sought to take advantage of the hedgehog-signaling expertise of Dr. David J. Robbins and the mammary stem cell and breast cancer expertise of Dr. James DiRenzo. What follows is a detailed description of progress towards the completion of the research supported by this award.

Research Accomplishments Associated with the Statement of Work

Task 1: Determine the effects of pharmacologic regulation of Smoothened on mammary stem cell quiescence.

Sub-Task 1: Evaluate the effects of Smo agonists on regulation of quiescence in $\text{Lin}^-/\text{CD24}^+/\text{CD29}^{\text{high}}$ cells.

- A: Establish a treatment model based on one utilized according to the Frank-Kamenetsky model (Frank-Kamenetsky et al., 2002).
 - 1: Isolate and quantify $\text{Lin}^-/\text{CD24}^+/\text{CD29}^{\text{high}}$ and $\text{Lin}^-/\text{CD24}^+/\text{CD29}^{\text{low}}$ to determine if the ratio of mammary stem cells to committed mammary progenitors is altered by Smo activation.
 - 2: Evaluate mammosphere initiating capacity of $\text{Lin}^-/\text{CD24}^+/\text{CD29}^{\text{high}}$ +/- Smo agonist.

- 3: Determine the effects of Smo agonists on engraftment efficiency, ductal elongation and side-branching.

Progress: We have encountered multiple technical obstacles in our efforts to establish an efficient treatment model that was based on the Frank-Kamenetsky model. This model called for the administration of Smoothened agonists via oral gavage and while we were able to administer the drug via this method we did not observe increased expression of LacZ in the $Ptch1^{LacZ/+}$ mice following administration indicating that regulation of the canonical hedgehog target gene, Patched1, was not altered in response to oral-gavage of Smoothened agonists. In vitro testing of the compounds indicated that they were able to activate endogenous expression of Patched1, suggesting that they are able to activate hedgehog signaling. The most likely reason for the inability to detect hedgehog activation following administration of the smoothened agonists via oral gavage is that the compounds may have poor pharmacokinetic or pharmacodynamics properties on the C57Bg/129 genetic background. Our solution to this problem was to adopt a genetic strategy to determine if hyperactivation of hedgehog signaling via loss of $Ptch1$ would:

1. Alter ratios of mammary stem cells to mammary progenitors.
2. Alter mammosphere-initiating capacity.
3. Alter engraftment efficiency or ductal elongation

Our rationale for this was that genetic activation of hedgehog signaling via Patched1 heterozygosity would mimic the effects of pharmacologic activation or smoothened. Therefore we would still be able to address whether or not hedgehog activation had any effect on mammary stem cell activity. We isolated mammary epithelial cells (MECs) from wt and $Ptch+/-$ mice by generating a single cell suspension from freshly dissected mammary glands. Quantification of enriched fractions of mammary stem cells ($Lin^{-}/CD24^{+}/CD29^{high}$) and mammary progenitors ($Lin^{-}/CD24^{+}/CD29^{low}$) indicated an increase in the luminal progenitor population, and a decrease in the mammary stem cell population in the $Ptch1+/-$ when relative to wt mice (Figure 1). These results are consistent with the previous finding that mammary stem cells from $Ptch1^{LacZ/+}$ mice are defective in quiescence and they support a model in which hedgehog signaling promotes the activation of the mammary regenerative hierarchy.

Wildtype Ptch1 +/-




Figure 1: Quantitative comparison of enriched fractions of mammary stem cells (Lin⁻/CD24⁺/CD29^{high}) and luminal epithelial progenitors (Lin⁻/CD24⁺/CD29^{low}) indicates increased elaboration of committed progenitors by committed stem cells. Data above indicate the prospective sorting strategy that was used to isolate Lin⁻/CD24⁺/CD29^{high} and Lin⁻/CD24⁺/CD29^{low} fractions. Results indicate a 20% decline in the size of the mammary stem cell pool and a 25% increase in the mammary progenitor pool in Ptch1^{LacZ/+} mice compared to wild-type littermates. This result is consistent with the hypothesis that hedgehog signaling activation results in increased mammary stem cell activity.

Consistent with the observation that hedgehog activation lead to increased mammary stem cell activity we also observed that enriched fractions of mammary stem cells from $Ptch1^{LacZ/+}$ formed mammospheres with increased efficiency relative to the same fraction from wild-type littermates. (Figure 2).




Figure 2: Comparative analysis of mammosphere forming capacity of enriched fractions of mammary stem cells from $Ptch1^{LacZ/+}$ and wild-type littermates. $Lin^{-}/CD24^{+}/CD29^{high}$ cells were isolated from 3 $Ptch1^{LacZ/+}$ and 3 wt littermates and cultured in ultra-low attachment culture dishes for 12 days. Spheres were stained with the vital fluorescent dye, Calcein EM and counted. Data represent the mean of three distinct experiments and error bars represent the standard deviation. Results indicate that hedgehog activation via Patched1 heterozygosity leads to increased mammosphere forming activity.

To better understand the biological significance of the increased mammary stem cell activity in the $Ptch1^{LacZ/+}$ mouse relative to age-matched wild-type mice we transplanted enriched fractions of mammary stem cells ($Lin^{-}/CD24^{+}/CD29^{high}$) from Rosa26 and $Ptch1^{LacZ/+}$ mice into the cleared fat pads of syngeneic hosts. Rosa26 mice were used in place of wild-type C57/B6 mice because the constitutive expression of Lacz would enable unambiguous detection of donor-derived mammary outgrowths. Results indicated that $Lin^{-}/CD24^{+}/CD29^{high}$ cells from $Ptch1^{LacZ/+}$ mice gave rise to ductal outgrowths with significantly more side-branching and precocious lobulo-alveolar formation (Figure 3)




Figure 3: Enhanced side-branching and lobulo-alveolar formation in ductal outgrowths derived from $Ptch1^{LacZ/+}$ mammary stem cells. One hundred $Lin^{-}/CD24^{+}/CD29^{high}$ cells from either $Ptch1^{LacZ/+}$ or Rosa26 mice were transplanted into the cleared fat pads of syngeneic recipients. At 6 weeks post transplant mammary wholemounts were prepared and stained with X-gal to detect donor-derived ductal outgrowths. Results indicate that constitutive activation of hedgehog signaling lead to activation of the mammary regenerative hierarchy.

Collectively these data support the conclusion that hedgehog activation stimulates mammary stem cell activity, thereby driving the mammary regenerative hierarchy. Additionally the

premature lobulo-alveolar formation is consistent with a model in which hedgehog-mediated activation of mammary stem cells results in elaboration of a luminal epithelial lineage. To test this enriched fractions of mammary stem cells ($\text{Lin}^-/\text{CD24}^+/\text{CD29}^{\text{high}}$) from wild-type and $\text{Ptch1}^{\text{LacZ}/+}$ littermates were cultured under conditions that promote the expansion of luminal epithelial colonies, myoepithelial colonies and mixed lineage colonies and colonies were stained with CK8 and CK5 to distinguish luminal epithelia from myoepithelia. This enabled to quantification of developmental endpoints and revealed that mammary stem cells from the $\text{Ptch1}^{\text{LacZ}/+}$ mouse model strongly favored the luminal epithelial cell fate over the mixed lineage cell fate (Figure 4).




Figure 2. Aberrant activation of Hedgehog pathway result in the transition from mammary stem cell to luminal progenitor cell. **A.** Two representative colonies for each mice group (wt and $\text{Ptch1}^{+/-}$) stained for CK5 and CK8, myoepithelial and luminal markers respectively. An absence of myoepithelial cells within the colony was observed in the $\text{Ptch1}^{+/-}$ colonies when compare to the wt. **B.** The relative number of mixed colonies in red (in which both luminal and myoepithelial cells are present), compare to the total number of colonies observed (Error bars represent standard deviation in technical replicates). The decrease in the number of myoepithelial cells in the heterozygous mice is indicative of the commitment of the stem cell population to luminal progenitors when HH pathway is activated.

Sub-Task 2: Evaluate the ability of Smo antagonists to rescue the $Ptch1^{-/+}$ phenotype.

A: Identical treatment model.

- 1: Isolate and quantify $Lin^{-}/CD24^{+}/CD29^{high}$ and $Lin^{-}/CD24^{+}/CD29^{low}$ to determine if the ratio of mammary stem cells to committed mammary progenitors is altered by Smo antagonism.
- 2: Evaluate mammosphere initiating capacity of $Lin^{-}/CD24^{+}/CD29^{high}$ from $Ptch1^{-/+}$ mice $-/+$ Smo antagonist.
- 3: Determine the effects of Smo agonists on engraftment efficiency, ductal elongation and sidebranching.

Progress: Similar to the studies involving in vivo administration of Smoothed Agonists we have encountered pharmacokinetic obstacles that have limited the biological activity of the Smoothed Antagonist, SANT1. Our in vitro studies indicated that the drug does oppose hedgehog signaling however we have seen no evidence of changes in hedgehog signaling status in vivo following administration of SANT1. To circumvent this problem and to address the effects of Smoothed inhibition on hedgehog signaling in mammary stem cells, we have purchased 5 lentiviral shRNA constructs designed to produce a knock-down of Smoothed. At the time of this report those constructs are being packaged into lentiviral particles and tested in vitro to determine which produced the most significant suppression of Smoothed expression. Once this is complete we intend to infect $Lin^{-}/CD24^{+}/CD29^{high}$ cells from wild-type and $Ptch1^{LacZ/+}$ mice with the selected viral particle and transplant those cells into cleared fat pads of syngeneic recipients. Our prediction is that suppression of Smoothed will rescue the aberrant side-branching and lobulo-alveolar formation phenotype in the $Ptch1^{LacZ/+}$ mouse. Additionally we predict that suppression of Smoothed in wild-type $Lin^{-}/CD24^{+}/CD29^{high}$ cells will lead to diminished ductal elongation and side-branching.

Progress on this sub-task has been remarkably challenging due to the limitation of the smoothed antagonists and the labor-intensive process of identifying the optimal lentiviral shRNA for suppression of Smoothed.

Task 2: Determine if hedgehog-mediated defective quiescence predisposes multiparous MMTV-myc mice to tumorigenesis.

Sub-Task 1: Genetic analysis: Cross FV/b MMTV-myc with B6/129 $Ptch1^{-/+}$

- | | |
|---------------------------------------|---|
| A: 25% $Ptch1^{+/+}$ + No MMTV-myc Tg | (WT on Mixed FV/bxB6/129 bkg) |
| B: 25% $Ptch1^{-/+}$ + No MMTV-myc Tg | (Ptch on Mixed FV/bxB6/129 bkg) |
| C: 25% $Ptch1^{+/+}$ + MMTV-myc Tg | (MMTV-myc on Mixed FV/bxB6/129 bkg) |
| D: 25% $Ptch1^{-/+}$ + MMTV-myc Tg | ($Ptch1^{-/+}$ + MMTV-myc Mixed FV/bxB6/129 bkg) |

- 1: Collect 8 females from each genotype and monitor for tumorigenicity over 12 months.

Progress: We have completed the genetic crosses necessary to produce a minimum of 8 mice with each genotype. We have also developed a Q-PCR-based assay that can identify $Ptch1^{LacZ/+}$ from wild-type and MMTV-myc Tg from wild-type. These mice are evaluated twice weekly by the PI and daily by the staff at the Animal Resource Facility. Presently we have observed tumors in 4 of the mice that are $Ptch1^{LacZ/+}$ and MMTV-myc Tg and 1 in mice that are $Ptch1^{+/+}$ and MMTV-myc Tg. Monitoring will continue through June of 2012 to ensure that the youngest these mice reach 1 year of age. These preliminary results may suggest that activation of hedgehog signaling via $Ptch1$ heterozygosity is promoting c-myc-mediated

tumorigenesis in nulliparous mice, however at the present we can not make that assertion conclusively. Table 1 (below) summarizes the data from these genetic studies.

Genotype	Number	Confirmed Tumorigenesis	Average age of Onset
Ptch1 ^{+/+} + MMTV-myc ^{-/-}	11	0	N/A
Ptch1 ^{+/+} + MMTV-myc ^{+/-}	10	1	7 months 2 days
Ptch1 ^{LacZ/+} + MMTV-myc ^{-/-}	8	0	
Ptch1 ^{LacZ/+} + MMTV-myc ^{+/-}	13	4	6 months 13 days

All tumors have been dissected fixed and embedded in paraffin for histologic analysis.

Sub-Task 2: “Pseudo-genetic analysis”

- A: Isolate Lin⁻/CD24⁺/CD29^{high} from MMTV-myc and infect with pGIPZ-non-specific shRNA or pGIPZ-mPtch1 shRNA
- B: Sort GFP-ve from GFP+ve.
- C: Transplant GFP+ve cells into cleared fat pads of 3 week old FV/B recipients
 - 1: Transplant 16 glands (i.e. 8 recipient mice) with Lin⁻/CD24⁺/CD29^{high} infected with pGIPZ-non-specific shRNA.
 - a: Monitor transplants for tumorigenesis over 12 months.
 - 2: Transplant 16 glands from 8 mice with Lin⁻/CD24⁺/CD29^{high} infected with with pGIPZ-mPtch1 shRNA.
 - a: Monitor transplants for tumorigenesis over 12 months.

Progress: Efforts to target expression of Patched1 in mammary stem cells from wild-type and MMTV-myc mice with lentiviral shRNA have been hampered by poor infection efficiency. Despite significant efforts to improve viral titers and optimize the physical and chemical conditions necessary for high efficiency we have consistently achieved less than 10% infection efficiency. Under these conditions it has not been possible to detect any suppression of Patched1. These poor efficiencies have made it difficult to isolate sufficient numbers of GFP-positive cells to continue with transplantation. Since the goal of the sub-task is to determine if there is a genetic interaction between hedgehog signaling and c-myc-mediated breast tumorigenesis, we are confident that the progress described above in Sub-task 1 will address that question.

Task 3: Evaluate the ability of hedgehog activation to sensitize tumor stem cells to taxanes in vitro and in vivo.

Sub-Task 1: In vitro studies

- A: Isolate Lin⁻/CD24⁺/CD29^{high} from wt and Ptch1^{-/+} mice and evaluate the effects of paclitaxel on mammosphere formation.
- B: Isolate Lin⁻/CD24⁺/CD29^{high} from wt mice and evaluate the ability of a Smoothened agonists to sensitize cells to paclitaxel.
 - 1: Isolation of Lin⁻/CD24⁺/CD29^{high} from wt mice
 - 2: Pre-treatment with paclitaxel.
 - 3: Culture under low-binding conditions that favor expansion of self-renewing populations.
- C: Isolate Lin⁻/CD24⁺/CD29^{high} from Ptch1^{-/+} mice and evaluate the ability of Smo antagonist to protect cells from paclitaxel.

Sub-Task 2: In vivo studies

A: Determine the efficiency of serial transplantation of tumors derived from MMTV-myc and Ptch1^{-/+} x MMTV-myc following paclitaxel treatment.

1: Cross FV/b MMTV-myc with B6/129 Ptch1^{-/+}

a: 25% Ptch1^{+/+} + No MMTV-myc Tg

b: 25% Ptch1^{-/+} + No MMTV-myc Tg

c: 25% Ptch1^{+/+} + MMTV-myc Tg

Progress: Efforts to determine whether hedgehog activation via the use of Smoothened agonists is sufficient to sensitize mammary stem cells to the spindle poison, paclitaxel are under way and several observations have been made.

First we noted that while mammary stem cells are resistant to paclitaxel in vivo, they are not when cultured in vitro. This difference very likely reflects the fact that cells from the Lin⁻/CD24⁺/CD29^{high} fraction are able to proliferate in culture which is inconsistent with their ability to retain BrdU for prolonged periods of time in vivo. This difference is also likely to reflect the protective effects of the mammary stem cell niche and the loss of these effects when cells are removed from the body of the mice. To address this we attempted to establish a sub-threshold dose of paclitaxel that was sufficient to cause the depolymerization of the mitotic tubule but not kill the cells in vitro. Our data indicate that while the sub-threshold doses of paclitaxel would support prolonged survival of mammary stem cells in culture, any dose that was sufficient to disrupt mitotic spindle activity was also sufficient to kill the Lin⁻/CD24⁺/CD29^{high} cells. These observations are consistent with our over-arching hypothesis that it is the state of proliferative quiescence observed within mammary stem cells in vivo that confers protection from cytotoxic chemotherapeutics. These studies strongly suggest that the only way to determine if hedgehog activators are able to sensitize mammary stem cells will be to determine if in vivo administration of these compounds is sufficient to subvert long-term label retention, as was noted in the Ptch1^{LacZ/+} mouse. This study is a derivative of that which is described in Sub-task 2A above in which we will take advantage of the known defect in cellular quiescence in mammary stem cells of Ptch1^{LacZ/+} mice. Our goal here will be to ask if this quiescence defect sensitizes Lin⁻/CD24⁺/CD29^{high} cells to paclitaxel which will result in a decrease in engraftment efficiency and ductal outgrowth. Our goal is to begin paclitaxel treatment by 4/1/2012 and complete the experiment by early June of 2012.

Key Research Accomplishments

1. Demonstration of a shift in the ratio of mammary stem cells to mammary progenitors in wild-type vs Ptch1^{LacZ/+} mice.
2. Demonstration of dramatically enhanced luminal epithelial commitment in response to constitutive hedgehog signaling in the Ptch1^{-/+} mouse.
3. Demonstration of enhanced formation of luminal mammospheres at the expense of bi-potent spheres by mammary stem cells from Ptch1^{-/+} mice relative to those from wild-type littermates.
4. Demonstration of a proliferative advantage, or quiescence defect in mammary stem cells in which hedgehog signaling is persistent.

5. Demonstration that the aberrant side-branching and precocious lobulo-alveolar development observed in the $Ptch1^{LacZ/+}$ mouse is a mammary stem cell autonomous effect.
6. Development of cohorts of MMTV-myc^{+/-}/ $Ptch1^{+/+}$ and MMTV-myc^{+/-}/ $Ptch1^{+/LacZ}$ for the determination of whether defective mammary stem cell quiescence is condition of breast cancer predisposition.
7. In vitro expansion of enriched fractions of mammary stem cells ($Lin^{-}/CD24^{+}/CD29^{high}$) by culturing on irradiated NIH3T3 cells.
8. Achieved ectopic expression of c-myc in mammary stem cells from wild-type and $Ptch1^{-}/+$ mice via retroviral transduction.

Reportable Outcomes

1. Publication of an article by Kent et al (attached as an appendix) in Cell Cycle describing the influence of Notch signaling on mammary stem cell quiescence. This research was a direct product of the findings associated with this award. More specifically our characterization of the molecular basis underlying the quiescence defect observed in the $Ptch1^{+/LacZ}$ lead to the identification of Notch3 as a transcriptional target of $\Delta Np63\alpha$ and a mediator of cellular quiescence in mammary stem cells.
2. Presentation of a poster describing progress associated with this award at the 2011 Era of Hope Conference in Orlando Florida
3. Seminar presentation at the University of Massachusetts describing the genetic interactions between $\Delta Np63\alpha$, hedgehog signaling and notch signaling. Much of the work described in this seminar was the product of research supported by this award.
4. Seminar presentation at the University of Vermont describing the genetic interactions between $\Delta Np63\alpha$, hedgehog signaling and notch signaling. Much of the work described in this seminar was the product of research supported by this award.
5. Seminar presentation at the Jackson Laboratory describing the genetic interactions between $\Delta Np63\alpha$, hedgehog signaling and notch signaling. Much of the work described in this seminar was the product of research supported by this award.

Conclusions

1. Data derived from this study support a model in which activation of hedgehog signaling is sufficient to stimulate mammary regenerative stasis. This conclusion is supported by the following findings:
 - a. Activation of hedgehog signaling via $Ptch1$ heterozygosity lead to:
 - i. Increased elaboration of mammary progenitors relative to mammary stem cells.
 - ii. Increased specification of luminal epithelial differentiation.

- iii. Increased mammosphere forming capacity
 - b. Transplantation of mammary stem cells derived from wild-type vs Ptch1 heterozygous mice resulted in increased side-branching and precocious lobuloalveolar development.
- 2. Preliminary data derived from this study indicate that activation of hedgehog signaling is sufficient to confer tumorigenesis upon nulliparous MMTV-myc mice. Kindreds associated with this study have not reached 1 year of age and so at this point no firm conclusions can be drawn.
- 3. Loss of quiescence in mammary stem cells confers sensitivity to paclitaxel. This conclusion is being tested more rigorously in ongoing studies.

References

- Coller, H.A., Sang, L., and Roberts, J.M. (2006). A new description of cellular quiescence. *PLoS Biol* 4, e83.
- Frank-Kamenetsky, M., Zhang, X.M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F.Y., Jones, S., Shulok, J., *et al.* (2002). Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothed agonists and antagonists. *Journal of biology* 1, 10.
- Hurt, E.M., and Farrar, W.L. (2008). Cancer stem cells: the seeds of metastasis? *Mol Interv* 8, 140-142.
- Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. *CA Cancer J Clin* 60, 277-300.
- Li, N., Singh, S., Cherukuri, P., Li, H., Yuan, Z., Ellisen, L.W., Wang, B., Robbins, D., and DiRenzo, J. (2008). Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. *Stem Cells* 26, 1253-1264.
- Mills, A.A., Zheng, B., Wang, X.J., Vogel, H., Roop, D.R., and Bradley, A. (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* 398, 708-713.
- Pardal, R., Clarke, M.F., and Morrison, S.J. (2003). Applying the principles of stem-cell biology to cancer. *Nat Rev Cancer* 3, 895-902.
- Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer* 9, 265-273.
- Woodward, W.A., Chen, M.S., Behbod, F., and Rosen, J.M. (2005). On mammary stem cells. *J Cell Sci* 118, 3585-3594.
- Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R.T., Tabin, C., Sharpe, A., Caput, D., Crum, C., *et al.* (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 398, 714-718.

Δ Np63 α promotes cellular quiescence via induction and activation of Notch3

Sierra Kent,^{1,2} Justine Hutchinson,^{1,2} Amanda Balboni,^{1,2} Andrew DeCastro,^{1,2} Pratima Cherukuri¹ and James DiRenzo^{1,*}

¹Department of Pharmacology and Toxicology; Dartmouth Medical School; Remsen, Hanover, NH USA; ²Program in Experimental Molecular Medicine; Dartmouth Medical School; Dartmouth Hitchcock Medical Center; Lebanon, NH USA

Key words: p63, Notch, quiescence, stem cell

Genetic analysis of TP63 indicates that Δ Np63 isoforms are required for preservation of self-renewing capacity in the stem cell compartments of diverse epithelial structures; however, the underlying cellular and molecular mechanisms remain incompletely defined. Cellular quiescence is a common feature of adult stem cells that may account for their ability to retain long-term replicative capacity while simultaneously limiting cellular division. Similarly, quiescence within tumor stem cell populations may represent a mechanism by which these populations evade cytotoxic therapy and initiate tumor recurrence. Here, we present evidence that Δ Np63 α , the predominant TP63 isoform in the regenerative compartment of diverse epithelial structures, promotes cellular quiescence via activation of Notch signaling. In HC11 cells, ectopic Δ Np63 α mediates a proliferative arrest in the 2N state coincident with reduced RNA synthesis characteristic of cellular quiescence. Additionally, Δ Np63 α and other quiescence-inducing stimuli enhanced expression of Notch3 in HC11s and breast cancer cell lines, and ectopic expression of the Notch3 intracellular domain (N3^{ICD}) was sufficient to cause accumulation in G₀/G₁ and increased expression of two genes associated with quiescence, Hes1 and Mxi1. Pharmacologic inhibition of Notch signaling or shRNA-mediated suppression of Notch3 were sufficient to bypass quiescence induced by Δ Np63 α and other quiescence-inducing stimuli. These studies identify a novel mechanism by which Δ Np63 α preserves long-term replicative capacity by promoting cellular quiescence and identify the Notch signaling pathway as a mediator of multiple quiescence-inducing stimuli, including Δ Np63 α expression.

Do not distribute.

Introduction

Cellular quiescence is implicated in maintenance of adult stem cells, and evidence indicates that defective quiescence leads to exhaustion of the stem cell pool.¹⁻⁷ Prolonged tissue stasis is achieved by coordinated regulation of regenerative hierarchies initiated by asymmetric division of an adult stem cell to produce mitotic offspring fated to retain or forfeit self-renewing capacity. While adult stem cells retain proliferative capacity, accumulating evidence indicates that they utilize cellular quiescence to restrict the number of divisions they undergo and to resist differentiation.⁸⁻¹⁰ Pulse labeling with nucleotide analogs has identified long-term label-retaining cells that have subsequently been shown to co-enrich with adult stem cells.^{4,11-16} Similarly, inducible expression of a GFP-histone2B fusion protein has enabled isolation of cells based on label retention and the subsequent demonstration that these cells possess potent stem cell activity.¹⁷⁻¹⁹ Slow-cycling or non-cycling cells within tumor populations selectively exhibit chemo-resistance and tumor-initiating capacity, suggesting that quiescence is a common feature among tumor stem cell populations²⁰⁻²³ and implying that pharmacologic disruption of stem cell quiescence in the setting of adjuvant therapeutics might reduce rates of cancer recurrence. Quiescence is an active process involving overlapping programs of gene regulation in response to

distinct quiescence-inducing stimuli.¹¹ Studies using fibroblasts identified serum deprivation early response genes (SDERGs) that were not coordinately repressed by serum stimulation, indicating a unique transcriptional response to serum deprivation.²⁴ Among the SDERGs, Notch3 was activated in less than one hour following serum deprivation. The canonical Notch target gene, Hes1 is activated in response to quiescence and is sufficient to maintain the reversible nature of quiescence.²⁵ These studies coupled to functional analysis of Notch signaling in MaSCs²⁶ implicate Notch signaling in adult stem cell quiescence.

The Notch signaling pathway executes context-dependent cell-fate decisions in diverse tissue types during embryonic patterning, stem cell regulation, proliferation, differentiation and apoptosis.²⁷⁻³¹ Notch activity is implicated in numerous malignancies and has been shown to be either an oncogene^{32,33} or a tumor suppressor^{28,34} in distinct cell types. It also governs aspects of development and tumorigenesis in the mammary gland.²⁷ Disruption of Notch signaling in the mammary gland via conditional deletion of RBPj (CBF1), causes expansion of the basal/myoepithelial cells and a concomitant loss of luminal epithelial cells, indicating that Notch signaling was important for luminal cell fate determination.³⁵ Additionally, suppression of CBF1 in enriched fractions of mammary stem cells (MaSCs) resulted in increased proliferation and mammary regenerative activity.²⁶

*Correspondence to: James DiRenzo; Email: James.DiRenzo@Dartmouth.edu
Submitted: 07/11/11; Accepted: 07/11/11
DOI: 10.4161/cc.10.18.17300




Figure 1. Δ Np63 α promotes cellular quiescence in HC11 cells. (A) Δ Np63 α suppresses proliferation of HC11 cells. Cells were infected with Adenovirus expressing Δ Np63 α or GFP and counted daily beginning 12 h after plating and infection. (Error bars represent standard deviation from two experiments). (B) Suppression of proliferation by Δ Np63 α is not a result of apoptosis. Following 48 h of adenoviral infection of Δ Np63 α or GFP, protein lysates were derived from all cells in the culture, and apoptosis was measured by protein gel blotting for PARP and cleaved PARP products indicative of apoptotic events. β -actin served as a loading control. (C) Δ Np63 α arrests HC11 cells in a state of 2N DNA content. Following 24 h of adenoviral expression of Δ Np63 α or GFP and 24-h thymidine synchronization, cells were washed and fed in the presence of nocodazole. A subpopulation of cells overexpressing Δ Np63 α arrested in G_0/G_1 of the cell cycle as evidenced by propidium iodide staining. (D) Cell cycle arrest induced by Δ Np63 α corresponds to the induction of cellular quiescence. Following Δ Np63 α or GFP overexpression, cells were fixed and assessed for a reduction in RNA content, indicative of cellular quiescence. Representative experiments are shown for (C and D).

Together, these results indicate that Notch signaling in the mammary gland contributes to at least two distinct cell fate decisions, luminal vs. basal/myoepithelial differentiation and quiescence vs. activation in MaSCs. Constitutive Notch signaling in the mammary gland results in a developmental blockade associated with decreased elaboration of alveoli during pregnancy, and this phenotype is believed to underlie tumorigenesis in this model.³⁶ Other studies have associated Notch signaling with the oncogenic activity of the Wnt signaling pathway in the mammary gland.³⁷

Genetic analysis clearly indicates that Δ Np63 products of *TP63* are required for preservation of self-renewal in diverse epithelial structures.^{38,39} More recent studies have indicated that Δ Np63 α is a potent blockade to cellular senescence;⁴⁰ however, it is unclear if this activity accounts for retention of proliferative capacity in adult stem cells. Here, we provide evidence that Δ Np63 α promotes cellular quiescence via the induction of Notch3 expression and activity. Δ Np63 α is sufficient to promote cellular quiescence, and Notch3 expression is induced by ectopic Δ Np63 α and other quiescence-inducing stimuli in HC11 cells. Other data indicate that ectopic activation of Notch signaling is sufficient to restrict proliferation in a manner that is independent of ectopic Δ Np63 α , and that genetic and pharmacologic repression of Notch signaling is sufficient to subvert cellular quiescence induced by ectopic Δ Np63 α or other quiescence-inducing stimuli. Our findings identify Notch signaling as a mediator of cellular quiescence and provide a novel mechanism by which Δ Np63 α mediates cellular quiescence and preservation of replicative capacity in adult stem cells.

Results

Δ Np63 α promotes cellular quiescence in HC11 cells. Previously, we reported a genetic interaction between Δ Np63 α and hedgehog signaling, demonstrating that Δ Np63 α preserves long-term replicative capacity via promotion of cellular quiescence.¹⁰ To further test this conclusion and characterize the mechanism(s) underlying Δ Np63 α -mediated quiescence, we adopted the HC11 cell line, which is an immortalized model of MaSCs possessing mammary regenerative capacity. Ectopic Δ Np63 α caused a significant reduction in cell number (Fig. 1A) with no observable increase in PARP cleavage (Fig. 1B), indicating that ectopic Δ Np63 α results in proliferative arrest and not apoptosis. To determine if the proliferative arrest was cellular quiescence, we monitored cell cycle progression of HC11s with ectopic GFP or Δ Np63 α . An 18-h thymidine blockade resolved populations that had or had not traversed the G_1/S checkpoint. Following this blockade, cells were released and allowed to progress to a nocodazole block in G_2 . Cell cycle distribution analysis indicated that ectopic Δ Np63 α , but not GFP, produced a fraction of cells that failed to progress to and traverse the G_1/S boundary (Fig. 1C). This result indicates that Δ Np63 α was sufficient to arrest cells in the 2N state under conditions in which there was sufficient mitogenic stimulation for GFP-expressing cells to progress to S phase. A common feature of cellular quiescence is decreased RNA biosynthesis, which can be detected by staining cells with pyronin Y.⁴¹ To determine whether

the Δ Np63 α -mediated accumulation in G₀/G₁ was the result of increased cellular quiescence, cells expressing Δ Np63 α or GFP were stained with the DNA dye Hoechst-33342 and pyronin Y and analyzed by flow cytometry. Results (Fig. 1D) indicate that ectopic Δ Np63 α resulted in accumulation of a pyronin Y^{low} subset of 2N cells. These results demonstrate that Δ Np63 α is able to promote cellular quiescence, suggesting a cellular mechanism by which it preserves long-term replicative capacity.

Notch3 is induced by ectopic Δ Np63 α and other quiescence-inducing stimuli. The previous result, coupled to studies linking Notch to TP63^{42,43} and to quiescence in fibroblasts²⁴ and MaSCs,²⁶ suggested that Notch signaling may contribute to Δ Np63 α -mediated quiescence. To test this, we sought to determine the effects of ectopic Δ Np63 α on expression of all four Notch family members. Results indicated that in HC11 cells, Notch3 expression increased in response to ectopic Δ Np63 α , while Notch1 and Notch2 were unaffected, and Notch4 expression declined (Fig. 2A). Induction of Notch3 by ectopic Δ Np63 α was also observed in MCF7 cells (Fig. 2B), suggesting that regulation of Notch3 by Δ Np63 α may be a common event in mammary epithelium. These results indicated a regulatory relationship between Δ Np63 α and Notch3, which further suggested that Δ Np63 α may contribute to Notch signaling. Protein gel blot analysis of Notch3 in HC11 cells overexpressing either GFP or Δ Np63 α indicated that ectopic Δ Np63 α caused increases in both full-length Notch3 and the truncated intracellular domain (Fig. 2C). Similarly, ectopic Δ Np63 α was sufficient to increase expression of Hes1 (Fig. 2D). Together, these results indicate that Δ Np63 α increases expression of Notch3 and activation of the Notch signaling pathway. These results coupled to studies linking Δ Np63 α to quiescence¹⁰ and Notch to quiescence^{11,24,43} suggest that Notch3 expression is a common feature of cellular quiescence. To test this, HC11s cells were cultured under normal monolayer conditions or under three distinct quiescence-inducing conditions, serum deprivation (SD), low-binding culture (LB) and contact inhibition (CI). QPCR-based analysis indicated increased




Figure 2. Notch3 is induced by ectopic Δ Np63 α and other quiescence-inducing stimuli. (A) Δ Np63 α specifically induces Notch3 mRNA in HC11 cells. Infection with adenovirus expressing Δ Np63 α or GFP for 48 h significantly induced Notch3 mRNA as assessed by qPCR ($p < 0.05$, Student t-test). (B) Δ Np63 α induces Notch3 mRNA in MCF7 breast cancer cells. (C) Δ Np63 α activates signaling of the Notch3 receptor. In addition to elevating total Notch3, Δ Np63 α overexpression also increases the amount of cleaved Notch3 intracellular domain, an indicator of active Notch signaling, as assessed by protein gel blot. (D) Δ Np63 α induces Hes1, a canonical Notch signaling target and mediator of cellular quiescence. (E) Notch3 is induced following multiple quiescence-promoting stimuli in addition to Δ Np63 α . As assessed by qPCR, Notch3 mRNA is elevated following serum deprivation (SD), low-binding culture (LB) and contact inhibition (CI) ($p < 0.05$).

Notch3 expression in response to each of these quiescence-inducing stimuli (Fig. 2E). Together, these results indicate that ectopic Δ Np63 α and other quiescence-inducing stimuli enhance expression of Notch3. They also suggest that expression of Notch3 may mediate the effects of Δ Np63 α and other quiescence-inducing stimuli.




Figure 3. Constitutive Notch3 activity is anti-proliferative and induces expression of quiescence-associated genes. (A) Overexpression of Notch3 intracellular domain (N3^{ICD}) by adenoviral infection of HC11 cells. β -actin as loading control. (B) Overexpression of N3^{ICD} activates Notch signaling. Relative luciferase activity from CBF-luc reporter following GFP or N3^{ICD} overexpression. (C) N3^{ICD} suppresses HC11 proliferation similar to Δ Np63 α . HC11 cells were trypsinized and counted every 12 h following plating and infection with adenoviral N3^{ICD} or GFP. (D and E) N3^{ICD} induces mRNA of canonical Notch signaling targets and quiescence-mediating genes. Overexpression of N3^{ICD} increases mRNA of the canonical Notch signaling target and regulator of quiescence, Hes1 (C) and the c-myc-regulating mediator of quiescence, Mxi1 (D) as assessed by qPCR ($p < 0.05$).

Constitutive Notch3 activity promotes quiescence. The previous data coupled to studies implicating Notch signaling in the governance of MaSCs proliferation²⁶ predict that Notch3 expression and signaling mediates Δ Np63 α -induced quiescence, and that activation of Notch signaling in HC11 cells will promote

quiescence. To test this, gain-of-function studies were performed by infecting HC11 cells with an adenovirus programmed to express the intracellular domain of Notch3 (N3^{ICD}) or GFP. Overexpression of N3^{ICD} (Fig. 3A) but not GFP was sufficient to activate a Notch signaling reporter consisting of four CBF1-binding elements fused to the SV40 minimal promoter.⁴⁴ In similar studies, N3^{ICD} had a potent anti-proliferative effect on HC11 cells (Fig. 3C) and was sufficient to induce Hes1 mRNA levels approximately 10-fold (Fig. 3C). The latter result indicates that ectopic N3^{ICD} was sufficient to activate expression of a canonical Notch signaling target gene. Additionally, Hes1 is required to preserve the reversibility associated with quiescence.²⁵ In addition to Hes1, N3^{ICD} also induced mRNA levels of Mxi1, a negative regulator of c-myc activity recently identified as a serum deprivation early response gene (SDERG) and shown to be essential for quiescence.²⁴ These studies demonstrate that Notch signaling is sufficient to arrest the growth of HC11 cells in a manner that is consistent with cellular quiescence.

Suppression of Notch3 disrupts quiescence and promotes expansion of self-renewing populations. The previous data indicated that ectopic Notch signaling reduced proliferation and increased expression of genes associated with cellular quiescence. This predicts that disruption of Notch signaling in HC11 cells might subvert quiescence. To test this, we sought to measure the effects of Notch disruption on BrdU incorporation rates following quiescence-inducing stimuli. Pharmacologic inhibition of Notch signaling with the γ -secretase inhibitor DAPT doubled the rate of BrdU incorporation following growth factor reduction (Fig. 4A), which supports the assertion that Notch-mediated growth arrest is reversible and consistent with cellular quiescence. Similarly, shRNA-mediated suppression of Notch3 (Fig. 4E) resulted in increased proliferation under growth factor-reduced conditions (Fig. 4B). These results indicate that disruption of Notch signaling or Notch3 expression is sufficient to confer resistance to quiescence-inducing stimuli and are consistent with previous studies indicating that suppression of Notch signaling in MaSCs results in mitotic expansion.²⁶ They also predict that suppression of Notch signaling will promote expansion of self-renewing subpopulations within HC11 cells. To test this, the mammosphere-forming capacity of HC11 cells was measured in the presence of DAPT or a vehicle control. Quantification of mammospheres indicated that inhibition of Notch signaling with DAPT caused a statistically significant increase in mammosphere initiation (Fig. 4C). Additionally, shRNA-mediated suppression of Notch3 resulted in greater mammosphere initiation relative to scrambled shRNA controls (Fig. 4D). These results demonstrate that Notch signaling exerts an anti-proliferative effect on self-renewing populations within the HC11 cell culture system.

Disruption of Notch signaling blocks Δ Np63 α -mediated cellular quiescence. Data presented here support a model in which Δ Np63 α promotes quiescence by increasing Notch3 expression and activity. This model predicts that suppression of Notch3 expression will disrupt Δ Np63 α -mediated cellular quiescence. We sought to compare the effects of ectopic Δ Np63 α on proliferation by HC11 derivatives programmed to express a scrambled shRNA or a Notch3-directed shRNA. Results (Fig. 5A) indicate

that suppression of Notch3 subverted the anti-proliferative effects of Δ Np63 α . Additionally, suppression of Notch3 expression disrupted Δ Np63 α -mediated accumulation of cells in the 2N state (Fig. 5B). Finally, suppression of Notch3 significantly reduced Δ Np63 α -mediated accumulation of pyronin Y^{low}-staining cells. Together, these results demonstrate that suppression of Notch3 expression (Fig. 5C) is sufficient to subvert Δ Np63 α -mediated cellular quiescence. These data strongly support a model in which the ability of Δ Np63 α to increase expression and activity of Notch3 is functionally linked to the ability of Δ Np63 α to promote cellular quiescence.

Discussion

Studies indicate that label-retaining cells co-purify with tissue-specific adult stem cells, suggesting a physiologic role for quiescence in preservation of self-renewal within regenerative hierarchies that govern development, stasis, aging and cancer. Central to this model is the functional asymmetry of stem cell division that yields mitotic siblings with distinct fates. While one sibling forfeits self-renewing capacity and enters a stage of transient amplification, a second retains it and enters a state of quiescence. Doing so enables retention of proliferative capacity and evasion of the negative effects of excessive cell division, including telomeric erosion, accumulation of reactive oxygen species and increased risk of mutation. Quiescence is also a potent blockade to differentiation,¹¹ suggesting a role in developmental potency. Despite the critical role of quiescence, the molecular and genomic events associated with entry into and maintenance of quiescence are incompletely understood. Work presented here describes a regulatory relationship between Δ Np63 α and Notch3 that governs quiescence and demonstrates for the first time that Δ Np63 α promotes quiescence and suggests a mechanism by which Δ Np63 α promotes stem cell longevity.

While the hypotheses surrounding the role of adult stem cells in cancer initiation and etiology remain controversial and unproven, there is abundant evidence indicating that diverse tumors possess a subpopulation of cells that are uniquely tumorigenic and able to self-renew. Multiple studies have demonstrated that this subpopulation displays broad-spectrum resistance to cytotoxic chemotherapeutics and ionizing radiation,⁴⁵⁻⁴⁷ thereby implicating this subpopulation in cancer recurrence. Other studies demonstrate a correlation between label retention and chemoresistance in cancer models, suggesting that cellular quiescence may confer resistance to therapeutics that target proliferating cells.²³ Consistent with this are studies indicating that subversion of quiescence in leukemic stem cells renders these cells sensitive to chemotherapeutics.⁴⁸ Therefore, targeting genetic pathways governing stem cell quiescence in the setting of adjuvant therapeutics represents a promising strategy to reduce cancer recurrence. Here, we present data indicating that disruption of Notch signaling subverts quiescence in a cell culture model with features of MaSCs. Additionally, we demonstrate that Notch signaling may mediate a cellular response to diverse quiescence-inducing stimuli, including Δ Np63 α activity, suggesting a fundamental role in cellular quiescence that may apply to multiple cancer stem cell models.




Figure 4. Disruption of Notch3 expression or activity prevents quiescence and promotes the expansion of self-renewing populations. (A) Pharmacologic inhibition of Notch signaling suppresses quiescence. Following serum deprivation in the presence of the γ -secretase inhibitor DAPT or control, DMSO, HC11 cells were pulsed with BrdU and fixed. Immunostaining for BrdU incorporation followed by counting of BrdU+ cells showed an increase in the number of cells synthesizing DNA in the presence of DAPT despite the quiescence-inducing effects of serum deprivation. (B) Genetic inhibition of Notch3 suppresses quiescence. Cells assayed as in (A), in the presence of Notch3-specific shRNA or control: a similar trend was seen when specifically targeting the Notch3 receptor. (C) DAPT treatment suppresses attachment-independent induced quiescence. Inhibiting Notch signaling increased the number of spheres formed in low-binding culture. (D) Notch3 suppression by shRNA also blocks attachment-independent induced quiescence. (E) Suppression of Notch3 mRNA by two independent Notch3-targeting shRNAs assessed by qPCR.

Cellular and developmental context are critical determinants of Notch signaling output that may account for the diverse cellular responses to perturbations in Notch signaling.²⁷⁻³⁰ This diversity is best illustrated by abundant and compelling evidence that




Figure 5. (A) Notch3 shRNA abrogates Δ Np63 α suppression of proliferation. HC11 cells expressing Notch3 shRNA or control were counted every 12 h following adenoviral expression of Δ Np63 α . (B) Notch3 suppression blocks the G₀/G₁ arrest induced by Δ Np63 α . HC11 cells expressing Notch3 shRNA or control were treated as in Figure 1C. Bar graph depicts the average number of cells with 2N DNA content. (C) Suppression of Notch3 blocks the quiescence inducing effects of Δ Np63 α . HC11 cells expressing Notch3 shRNA or control were infected with Δ Np63 α -expressing adenovirus and assessed as in Figure 1D.

Notch signaling can be either oncogenic or tumor suppressive in distinct cellular contexts. A model that may account for this variability holds that Notch signaling instructs mutually exclusive cell fates upon Notch donor and recipient cells via lateral inhibition;⁴² however, the molecular determinants of context specificity are largely unidentified. Within the context of governance of stem cell quiescence, our study suggests that Δ Np63 α may be one such determinant of Notch signaling output. Additionally, it is unclear whether the four Notch family members mediate identical Notch signaling outputs. In this manuscript, we reported that while only Notch3 was responsive to Δ Np63 α , both Notch1 and Notch2 were expressed at higher levels. This may suggest that effects of DAPT are due to inhibition of signaling from multiple Notch

receptors. In this manuscript we present data indicating that shRNA-mediated ablation of Notch3 was sufficient to prevent quiescence following growth factor reduction. Our data indicate that Notch signaling is anti-proliferative and promotes expression of genes associated with quiescence and support a model in which activation of Notch by Δ Np63 α represents a mechanism by which stem cell quiescence is maintained. Consistent with this model is the remarkable finding that the mammary glands of MMTV-Notch1^{ICD} and MMTV-Notch3^{ICD} undergo a developmental blockade that disrupts lobulo-alveolar development in pregnant mice.³⁶ This is in contrast to several other MMTV-based breast cancer models characterized by precocious lobulo-alveolar development and is consistent with a model in which Notch signaling suppresses activation of the mammary regenerative hierarchy.

Two recent studies have also implicated p53 in the governance of stem cell activity. One identified necdin as a gene that is regulated by p53 in the absence of any cellular or genotoxic stress and showed that necdin was necessary to maintain the ratio of long-term hematopoietic stem cells to short-term hematopoietic stem cells.⁴⁹ A second study showed that p53^{-/-} mammary epithelial cells had greater mammosphere-forming capacity and greater mammary regenerative capacity than mammary epithelial cells from wild-type counterparts.⁵⁰ Importantly this study showed that the increased regenerative activity that resulted from p53 ablation was neutralized by DAPT, suggesting strongly that Notch signaling was activated in response to p53 suppression. This study also showed that long-term BrdU retention was compromised in p53^{-/-} mice. Collectively, these studies indicate that a complex relationship between Δ Np63 isoforms and p53 may underlie the governance of quiescence vs. activation in adult stem cell populations.

Our conclusion that Δ Np63 α promotes cellular quiescence coupled to studies indicating that it is required to avoid cellular senescence^{40,51,52} suggests a dynamic model in which Δ Np63 α balances quiescence and senescence to preserve long-term replicative capacity and a prolonged life span. While there is abundant evidence that p53 is a potent inducer of cellular senescence, more recent studies have indicated that it can also promote quiescence and, in so doing, prevent senescence. Importantly, this study demonstrated that the ability of p53 to induce quiescence is the result of p53-mediated suppression of senescence.⁵³ While the cellular and molecular mechanisms underlying this paradox are incompletely understood, another recent study has implicated the status of the mTOR signaling pathway in the p53-mediated outcome.⁵⁴ Additionally, Δ Np63 α has been shown to be a transcriptional target of p53.⁵⁵ This coupled to the fact that Δ Np63 α is expressed in a highly cell-type dependent manner suggests a model in which cells that are capable of p53-dependent regulation of Δ Np63 α may be prone to quiescence, while those in which p53 is present but Δ Np63 α expression is repressed may be prone to senescence.

Materials and Methods

Cell culture. HC11 cells (a kind gift from Sergei Tevosian) were cultured in RPMI-1640 with L-glutamine (Mediatech Inc.)

supplemented with 10% FBS, 5 ug/ml Insulin, 10 ng/ml EGF, 100 units/ml Penicillin, 100 ug/ml Streptomycin, and MCF7 cells were cultured in DMEM supplemented with 10% FBS at 37°C and 5% CO₂. Serum deprivation studies involved culturing cells in a 100-fold dilution of normal media for 14 h. Low-binding assays were performed in 24-well Ultra Low Cluster plates (Corning) with normal media. Sphere counting was done using ImageJ software based on three low power images for each sample. Following growth to confluence, media was replaced and cells were maintained for two additional days to allow for contact inhibition. Cell counting experiments were done following trypsinization and counting by hemocytometer.

Cell cycle analysis. For cell cycle analysis based on propidium iodide or Hoechst/pyronin staining followed by flow cytometry, cells were treated as described, detached by trypsinization, resuspended in PBS, fixed in a final concentration of ice-cold 70% EtOH and stored overnight at -20°C prior to analysis. For propidium iodide staining, cells were washed in PBS, resuspended in PBS with 0.1% Triton X-100, 0.2 mg/ml DNase-free RNase A and 40 ul of 500 ug/ml propidium iodide stock and incubated at 37°C for 30 min. For Hoechst/pyronin staining, cells were washed in HBSS with Ca²⁺ and Mg⁺⁺ and resuspended in HBSS containing 1.2 ug/ml Hoechst 33,342 and 2 ug/ml pyronin Y. Flow cytometry was performed on a BD FacScan or BD FACS Aria for propidium iodide or Hoechst/pyronin Y, respectively. For synchronization, cells were treated with 2 mM thymidine or 100 ng/ml nocodazole. To assess S-phase fraction, cells were pulsed with 10 uM Bromodeoxy Uridine (BrdU) for 20 min followed by fixation with CytoRich Red (Thermo Fisher Scientific). BrdU was detected with mouse anti-BrdU (BD Bioscience) and goat anti-mouse AlexaFluor 568 (Invitrogen). Number of BrdU-positive cells per total cells from four high power fields were counted for each sample.

Adenovirus and lentivirus. ΔNp63α and Notch3 intracellular domain were sub-cloned from pcDNA3.1 into pShuttleCMV and further recombined through the AdEasy Adenoviral production system using HEK-293Ad cells. Adenovirus was used as 1,000x

for all reactions. pLKO.1-Notch3 shRNAs (OpenBiosystems, TRCN0000075571 “shRNA1,” TRCN0000075572 “shRNA2”) were cotransfected with packaging and envelope containing plasmids into HEK-293T cells. Virus-containing media was used to infect HC11 cells, and stable expressing populations were selected and grown in the presence of puromycin. Data from shRNA1 expressing cells are shown unless otherwise specified.

Notch inhibition. Cleavage of Notch receptors was blocked by inhibition of γ-secretase with 10 μM DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, Sigma).

Luciferase reporter assay. DNA fragment coding for EGFP was removed from CBFRE-EGFP (Addgene) and replaced with DNA fragment coding for luciferase to produce CBF-luc plasmid. Cells were treated as described and transfected with CBF-luc and renilla for 24 h. Luciferase activity was assessed with Dual-Luciferase Reporter Assay System (Promega).

Quantitative PCR and protein gel blotting. RNA was collected with the RNEasy kit (QIAGEN), and cDNA was prepared using the iScript cDNA Synthesis kit (BioRad). QPCR was performed with oligonucleotide primers specific for each target with iQ SYBR Green Super mix (BioRad) and analyzed with Bio-Rad CFX Manager software. Normalization with GAPDH was done using the 2^{-ΔΔCt} method. Protein gel blotting of protein lysates prepared with NET-N lysis buffer following PAGE was performed with antibodies detecting PARP (rabbit, Cell Signaling Inc.), p63 (mouse, 4A4, Abcam), Notch3 (goat, M-20, Santa Cruz) or β-actin (mouse, 8H10D10, Cell Signaling Inc.).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by grants from the National Cancer Institute (RO1CA108539) to J.D.R. and the Elsa U. Pardee Foundation to J.D.R. S.K. was supported by a fellowship from the Rosaline Borison Memorial Predoctoral Fellowship.

References

- Adams G. Investigation of Wnt signaling specifically in the hematopoietic stem cell niche identifies its role in maintaining stem cell quiescence and self-renewal. *Regen Med* 2008; 3:661-4; DOI:10.2217/17460751.3.5.661.
- Ficara F, Murphy MJ, Lin M, Cleary ML. Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. *Cell Stem Cell* 2008; 2:484-96; PMID:18462698; DOI:10.1016/j.stem.2008.03.004.
- Horsley V, Aliprantis AO, Polak L, Glimcher LH, Fuchs E. NFATc1 balances quiescence and proliferation of skin stem cells. *Cell* 2008; 132:299-310; PMID:18243104; DOI:10.1016/j.cell.2007.11.047.
- Passegué E, Wagers AJ. Regulating quiescence: new insights into hematopoietic stem cell biology. *Dev Cell* 2006; 10:415-7; PMID:16580989; DOI:10.1016/j.devcel.2006.03.002.
- He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 2004; 36:1117-21; PMID:15378062; DOI:10.1038/ng1430.
- Kobiela K, Stokes N, de la Cruz J, Polak L, Fuchs E. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling. *Proc Natl Acad Sci USA* 2007; 104:10063-8; PMID:17553962; DOI:10.1073/pnas.0703004104.
- Mira H, Andreu Z, Suh H, Lie DC, Jessberger S, Consiglio A, et al. Signaling through BMPR-1A regulates quiescence and long-term activity of neural stem cells in the adult hippocampus. *Cell Stem Cell* 2010; 7:78-89; PMID:20621052; DOI:10.1016/j.stem.2010.04.016.
- Clarke RB, Anderson E, Howell A, Potten CS. Regulation of human breast epithelial stem cells. *Cell Prolif* 2003; 36:45-58; PMID:14521515; DOI:10.1046/j.1365-2184.36.s.1.5.x.
- De Paiva CS, Pflugfelder SC, Li DQ. Cell size correlates with phenotype and proliferative capacity in human corneal epithelial cells. *Stem Cells* 2006; 24:368-75; PMID:16123387; DOI:10.1634/stemcells.2005-0148.
- Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellisen LW, et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. *Stem Cells* 2008; 26:1253-64; PMID:18292212; DOI:10.1634/stemcells.2007-0691.
- Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. *PLoS Biol* 2006; 4:83; PMID:16509772; DOI:10.1371/journal.pbio.0040083.
- Cotsarelis G. Epithelial stem cells: a folliculocentric view. *J Invest Dermatol* 2006; 126:1459-68; PMID:16778814; DOI:10.1038/sj.jid.5700376.
- Harnes DC, DiRenzo J. Cellular quiescence in mammary stem cells and breast tumor stem cells: got testable hypotheses? *J Mammary Gland Biol Neoplasia* 2009; 14:19-27; PMID:19240987; DOI:10.1007/s10911-009-9111-2.
- Welm B, Behbod F, Goodell MA, Rosen JM. Isolation and characterization of functional mammary gland stem cells. *Cell Prolif* 2003; 36:17-32; PMID:14521513; DOI:10.1046/j.1365-2184.36.s.1.3.x.
- Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. *Dev Biol* 2002; 245:42-56; PMID:11969254; DOI:10.1006/dbio.2002.0625.
- Woodward WA, Chen MS, Behbod F, Rosen JM. On mammary stem cells. *J Cell Sci* 2005; 118:3585-94; PMID:16105882; DOI:10.1242/jcs.02532.

17. Fuchs E. The tortoise and the hair: slow-cycling cells in the stem cell race. *Cell* 2009; 137:811-9; PMID:19490891; DOI:10.1016/j.cell.2009.05.002.
18. Fuchs E, Tumber T, Guasch G. Socializing with the neighbors: stem cells and their niche. *Cell* 2004; 116:769-78; PMID:15035980; DOI:10.1016/S0092-8674(04)00255-7.
19. Tumber T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. *Science* 2004; 303:359-63; PMID:14671312; DOI:10.1126/science.1092436.
20. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer* 2007; 7:834-46; PMID:17957189; DOI:10.1038/nrc2256.
21. Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, et al. Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues. *Leukemia* 2009; 23:1708-15; PMID:19641523; DOI:10.1038/leu.2009.142.
22. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. *Nat Biotechnol* 2010; 28:275-80; PMID:20160717.
23. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. *Breast Cancer Res* 2008; 10:25; PMID:18366788; DOI:10.1186/bcr1982.
24. Liu H, Adler AS, Segal E, Chang HY. A transcriptional program mediating entry into cellular quiescence. *PLoS Genet* 2007; 3:91; PMID:17559306; DOI:10.1371/journal.pgen.0030091.
25. Sang L, Collier HA, Roberts JM. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. *Science* 2008; 321:1095-100; PMID:18719287; DOI:10.1126/science.1155998.
26. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, et al. Notch signaling regulates mammary stem cell function and luminal cell fate commitment. *Cell Stem Cell* 2008; 3:429-41; PMID:18940734; DOI:10.1016/j.stem.2008.08.001.
27. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. *J Mammary Gland Biol Neoplasia* 2004; 9:145-63; PMID:15300010; DOI:10.1023/B:JOMG.0000037159.63644.81.
28. Dotto GP. Notch tumor suppressor function. *Oncogene* 2008; 27:5115-23; PMID:18758480; DOI:10.1038/onc.2008.225.
29. Efstratiadis A, Szabolcs M, Klinakis A. Notch, Myc and breast cancer. *Cell Cycle* 2007; 6:418-29; PMID:17329972; DOI:10.4161/cc.6.4.3838.
30. Lefort K, Dotto GP. Notch signaling in the integrated control of keratinocyte growth/differentiation and tumor suppression. *Semin Cancer Biol* 2004; 14:374-86; PMID:15288263; DOI:10.1016/j.semcancer.2004.04.017.
31. Robinson GW. Using notches to track mammary epithelial cell homeostasis. *Cell Stem Cell* 2008; 3:359-60; PMID:18940725; DOI:10.1016/j.stem.2008.09.014.
32. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G, et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. *Genes Dev* 1992; 6:345-55; PMID:1372276; DOI:10.1101/gad.6.3.345.
33. Robbins J, Blondel BJ, Gallahan D, Callahan R. Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. *J Virol* 1992; 66:2594-9; PMID:1312643.
34. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfshoten I, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. *Genes Dev* 2007; 21:562-77; PMID:17344417; DOI:10.1101/gad.1484707.
35. Buono KD, Robinson GW, Martin C, Shi S, Stanley P, Tanigaki K, et al. The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. *Dev Biol* 2006; 293:565-80; PMID:16581056; DOI:10.1016/j.ydbio.2006.02.043.
36. Hu C, Dievart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. *Am J Pathol* 2006; 168:973-90; PMID:16507912; DOI:10.2353/ajpath.2006.050416.
37. Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. *Proc Natl Acad Sci USA* 2006; 103:3799-804; PMID:16501043; DOI:10.1073/pnas.0600065103.
38. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. *Nature* 1999; 398:708-13; PMID:10227293; DOI:10.1038/19531.
39. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing and dominant-negative activities. *Mol Cell* 1998; 2:305-16; PMID:9774969; DOI:10.1016/S1097-2765(00)80275-0.
40. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, et al. DeltaNp63alpha Is an Oncogene that Targets Chromatin Remodeler Lsh to Drive Skin Stem Cell Proliferation and Tumorigenesis. *Cell Stem Cell* 2011; 8:164-76; PMID:21295273; DOI:10.1016/j.stem.2010.12.009.
41. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. *Cell Stem Cell* 2007; 1:324-37; PMID:18371366; DOI:10.1016/j.stem.2007.05.019.
42. Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. *Nat Rev Cancer* 2009; 9:587-95; PMID:19609265; DOI:10.1038/nrc2675.
43. Nguyen BC, Lefort K, Mandinova A, Antonini D, Devgan V, Della Gatta G, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. *Genes Dev* 2006; 20:1028-42; PMID:16618808; DOI:10.1101/gad.1406006.
44. Yu X, Zou J, Ye Z, Hammond H, Chen G, Tokunaga A, et al. Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. *Cell Stem Cell* 2008; 2:461-71; PMID:18462696; DOI:10.1016/j.stem.2008.03.001.
45. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 2009.
46. Passequé E, Rafii S, Herlyn M. Cancer stem cells are everywhere. *Nat Med* 2009; 15:23; PMID:19129778; DOI:10.1038/nm109-23.
47. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. *J Natl Cancer Inst* 2006; 98:1777-85; PMID:17179479; DOI:10.1093/jnci/djj495.
48. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. *Mol Oncol* 2010; 4:443-50; PMID:20599449; DOI:10.1016/j.molonc.2010.06.001.
49. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. *Cell Stem Cell* 2009; 4:37-48; PMID:19128791; DOI:10.1016/j.stem.2008.11.006.
50. Tao L, Roberts AL, Dunphy KA, Bigelow C, Yan H, Jerry DJ. Repression of Mammary Stem/Progenitor Cells by p53 is Mediated by Notch and Separable from Apoptotic Activity. *Stem Cells* 2010.
51. Keyes WM, Mills AA. p63: a new link between senescence and aging. *Cell Cycle* 2006; 5:260-5; PMID:16434880; DOI:10.4161/cc.5.3.2415.
52. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. *Genes Dev* 2005; 19:1986-99; PMID:16107615; DOI:10.1101/gad.342305.
53. Demidenko ZN, Korotchikina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. *Proc Natl Acad Sci USA* 2010; 107:9660-4; PMID:20457898; DOI:10.1073/pnas.1002298107.
54. Korotchikina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. *Aging (Albany NY)* 2010; 2:344-52; PMID:20606252.
55. Harnes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, et al. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. *Oncogene* 2003; 22:7607-16; PMID:14576823; DOI:10.1038/sj.onc.1207129.